Protein C Concentrate (Human)
drugOn this page
Also known as CeprotinHuman protein cProtein cProtein c (coagulation inhibitor)Protein c (homo sapiens)Protein c component of balfaxarProtein c humanProtexel
Summary
Protein C Concentrate (Human) (CHEMBL5315087) is an approved unknown (ATC B01AD12); indicated across 4 conditions including hereditary thrombophilia due to congenital protein c deficiency and purpura fulminans.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: B01AD12
- Indications: 4 conditions
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5315087 |
| Name | Protein C Concentrate (Human) |
| Type | Unknown |
| Max phase | 4 |
| ATC | B01AD12 |
Also known as: Ceprotin, Human protein c, Protein c, Protein c (coagulation inhibitor), Protein c (homo sapiens), Protein c component of balfaxar, Protein c concentrate (human), Protein c human, Protexel, PROTEIN C CONCENTRATE (HUMAN)
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hereditary thrombophilia due to congenital protein C deficiency | 4 | MONDO:0019145 | EFO:0009316 |
| purpura fulminans | 4 | MONDO:0000809 | EFO:1001913 |
| thrombotic disease | 4 | MONDO:0000831 | HP:0004419 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04219449 | Not specified | NOT_YET_RECRUITING | Thrombophilia In Beta Thalassemia |
| NCT01127529 | Not specified | COMPLETED | Ceprotin Treatment Registry |
| NCT07036809 | Not specified | COMPLETED | Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).